JP2012505253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505253A5 JP2012505253A5 JP2011531244A JP2011531244A JP2012505253A5 JP 2012505253 A5 JP2012505253 A5 JP 2012505253A5 JP 2011531244 A JP2011531244 A JP 2011531244A JP 2011531244 A JP2011531244 A JP 2011531244A JP 2012505253 A5 JP2012505253 A5 JP 2012505253A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- patient
- cyproterone acetate
- agent according
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000978 cyproterone acetate Drugs 0.000 claims description 23
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 23
- 239000002552 dosage form Substances 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 10
- 230000001457 vasomotor Effects 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004977 anhydrous lactose Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 19
- 229940124597 therapeutic agent Drugs 0.000 claims 19
- 238000000034 method Methods 0.000 description 19
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13689308P | 2008-10-10 | 2008-10-10 | |
| US61/136,893 | 2008-10-10 | ||
| PCT/US2009/060381 WO2010042930A1 (en) | 2008-10-10 | 2009-10-12 | Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012505253A JP2012505253A (ja) | 2012-03-01 |
| JP2012505253A5 true JP2012505253A5 (enExample) | 2013-06-06 |
Family
ID=42101000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531244A Pending JP2012505253A (ja) | 2008-10-10 | 2009-10-12 | 低用量酢酸シプロテロンを用いる、去勢された前立腺癌患者における血管運動症状の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8288342B2 (enExample) |
| EP (1) | EP2381946A4 (enExample) |
| JP (1) | JP2012505253A (enExample) |
| AU (1) | AU2009303272A1 (enExample) |
| BR (1) | BRPI0914024A2 (enExample) |
| CA (1) | CA2739887A1 (enExample) |
| EA (1) | EA022208B1 (enExample) |
| MX (1) | MX2011003726A (enExample) |
| WO (1) | WO2010042930A1 (enExample) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2345377A1 (de) | 1973-09-06 | 1975-03-20 | Schering Ag | Pharmazeutische zubereitung i |
| DE2817157A1 (de) * | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| DE3331824A1 (de) * | 1983-09-01 | 1985-03-21 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Verfahren zur herstellung von 17(alpha)-acyloxy-6-chlor-1(alpha),2(alpha)-methylen-3,20-dionen |
| DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
| US4498420A (en) * | 1984-01-23 | 1985-02-12 | Container Corporation Of America | Carton for insects |
| DE3934656A1 (de) * | 1989-10-13 | 1991-04-18 | Schering Ag | Verfahren zur herstellung von waessrigen dispersionen |
| DE3936328A1 (de) * | 1989-10-27 | 1991-05-02 | Schering Ag | Pharmazeutische praeparate |
| IE67345B1 (en) * | 1991-03-12 | 1996-03-20 | Akzo Nv | Low dose dry pharmaceutical preparations |
| US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| BE1007402A5 (nl) * | 1993-03-26 | 1995-06-06 | Adir | Nasale farmaceutische preparaten met progestagene stof. |
| US6165504A (en) * | 1998-09-23 | 2000-12-26 | Barr Laboratories, Inc. | Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients |
| US6613758B1 (en) * | 1999-04-02 | 2003-09-02 | Barr Laboratories, Inc. | Method for treating osteoporosis in castrated prostatic cancer patients |
| FR2821555B1 (fr) * | 2001-03-01 | 2003-05-16 | Besins Int Lab | Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations |
| US20040024230A1 (en) * | 2002-04-29 | 2004-02-05 | Boehringer Ingelheim International Gmbh | Synthesis of cyproterone acetate |
| US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| US7371405B2 (en) * | 2003-12-22 | 2008-05-13 | Mcneil-Ppc, Inc. | Consumer customized dosage forms |
| MY142989A (en) * | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
-
2009
- 2009-10-12 US US12/577,600 patent/US8288342B2/en not_active Expired - Fee Related
- 2009-10-12 WO PCT/US2009/060381 patent/WO2010042930A1/en not_active Ceased
- 2009-10-12 MX MX2011003726A patent/MX2011003726A/es active IP Right Grant
- 2009-10-12 JP JP2011531244A patent/JP2012505253A/ja active Pending
- 2009-10-12 AU AU2009303272A patent/AU2009303272A1/en not_active Abandoned
- 2009-10-12 BR BRPI0914024A patent/BRPI0914024A2/pt not_active Application Discontinuation
- 2009-10-12 EP EP09820034A patent/EP2381946A4/en not_active Withdrawn
- 2009-10-12 CA CA2739887A patent/CA2739887A1/en not_active Abandoned
- 2009-10-12 EA EA201170414A patent/EA022208B1/ru not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI595873B (zh) | 用於治療中樞誘發噁心及嘔吐之組成物及方法 | |
| JP5973411B2 (ja) | 医薬組成物 | |
| RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
| JP2013511507A5 (enExample) | ||
| RS55206B1 (sr) | Kompozicije za lečenje centralno posredovane mučnine i povraćanja | |
| RU2011138490A (ru) | Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон | |
| MX2010005680A (es) | Composiciones de tapentadol. | |
| JP2018507243A5 (enExample) | ||
| JP2011509295A5 (enExample) | ||
| AU2014216373B2 (en) | Pharmaceutical compositions for the treatment of Helicobacter pylori | |
| JP2011503063A5 (enExample) | ||
| KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
| JP2013541583A (ja) | 組み合わせ組成物 | |
| AU2014299447B2 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| BR112019027286B1 (pt) | Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva | |
| JP2009517411A5 (enExample) | ||
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 | |
| RU2261098C2 (ru) | Перорально распадающаяся композиция, содержащая миртазапин | |
| JP2004525940A (ja) | 火照りの処置のためのデュロキセチン | |
| Karunakar et al. | Comparative evaluation of efficacy of diclofenac and ketoprofen administered using transdermal drug delivery route in management of post endodontic pain: A randomized controlled clinical trial | |
| EA004474B1 (ru) | Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола | |
| CA3222959A1 (en) | Naltrexone for boosting the therapeutic utility of 5-ht receptor agonists | |
| CN104936585B (zh) | 包括苯肾上腺素和扑热息痛的组合药剂 | |
| JP2012505253A5 (enExample) |